Item 8.01 Other Events
On May 2, 2022, Alaunos Therapeutics, Inc. (the "Company") issued a press
release announcing the dosing of the first patient in its TCR-T Library Phase
1/2 Trial targeting KRAS, TP53 and EGFR mutations across six solid tumor
indications using the Company's non-viral Sleeping Beauty transposon/transposase
technology. The Company continues to expect to announce interim data from the
TCR-T Library Phase 1/2 Trial in the second half of 2022. A copy of the press
release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release, dated May 2, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses